APA (7th ed.) Citation

J, W., M, I., L, S., P, V., M, S., O, H., . . . CS, S. (2020). Cost-Effectiveness Analysis of Patiromer in Combination with Renin-Angiotensin-Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden. PharmacoEconomics, 38(7), 747. https://doi.org/10.1007/s40273-020-00902-w

Chicago Style (17th ed.) Citation

J, Widén, Ivarsson M, Schalin L, Vrouchou P, Schwenkglenks M, Heimbürger O, Ademi Z, and Sutherland CS. "Cost-Effectiveness Analysis of Patiromer in Combination with Renin-Angiotensin-Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden." PharmacoEconomics 38, no. 7 (2020): 747. https://doi.org/10.1007/s40273-020-00902-w.

MLA (9th ed.) Citation

J, Widén, et al. "Cost-Effectiveness Analysis of Patiromer in Combination with Renin-Angiotensin-Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden." PharmacoEconomics, vol. 38, no. 7, 2020, p. 747, https://doi.org/10.1007/s40273-020-00902-w.